Pharmacogenomic Prescribing Guidelines: Are They Always Useful?
- PMID: 39101255
- DOI: 10.1002/cpt.3403
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?
References
- 
    - Ingelman‐Sundberg, M. & Pirmohamed, M. Precision medicine in cardiovascular therapeutics: evaluating the role of pharmacogenetic analysis prior to drug treatment. J. Intern. Med. 295, 583–598 (2024).
 
- 
    - CPIC® Guideline for Clopidogrel and CYP2C19 <https://cpicpgx.org/guidelines/guideline‐for‐clopidogrel‐and‐cyp2c19/>.
 
- 
    - Duarte, J.D. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 genotypes and Beta‐blocker therapy. Clin. Pharmacol. Ther. 116, 939–947 (2024).
 
- 
    - Collett, S. et al. Metoprolol and CYP2D6: a retrospective cohort study evaluating genotype‐based outcomes. J Pers Med. 13, 416 (2023).
 
- 
    - Meloche, M. , Khazaka, M. , Kassem, I. , Barhdadi, A. , Dubé, M.P. & de Denus, S. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta‐analysis. Br. J. Clin. Pharmacol. 86, 1015–1033 (2020).
 
MeSH terms
LinkOut - more resources
- Full Text Sources
 
        